scholarly journals Prognostic Value of Tc-99m-MIBI Performed During Middle Course of Preoperative Chemotherapy in Patients With Malignant Bone and Soft-Tissue Tumors

2012 ◽  
Vol 37 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Hiroshi Wakabayashi ◽  
Junichi Taki ◽  
Anri Inaki ◽  
Hisashi Sumiya ◽  
Yoh Zen ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Preoperative Chemotherapy ◽  
Prognostic Value ◽  
Soft Tissue Tumors

scholarly journals Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: Comparison with Tl-201 imaging

2008 ◽  
Vol 26 (3) ◽  
pp. 411-418 ◽  
Author(s):  
Junichi Taki ◽  
Takahiro Higuchi ◽  
Hisashi Sumiya ◽  
Hiroyuki Tsuchiya ◽  
Hiroshi Minato ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Preoperative Chemotherapy ◽  
Tumor Response ◽  
Soft Tissue Tumors

scholarly journals Prognostic Value of the Doubling Time of Serum C-reactive Protein and Alkaline Phosphatase Levels in Primary Bone and Soft Tissue Tumors

1996 ◽  
Vol 87 (12) ◽  
pp. 1288-1295 ◽  
Author(s):  
Kazuo Yudoh ◽  
Hisao Matsui ◽  
Masahiko Kamanori ◽  
Kazuo Ohmori ◽  
Taketosi Yasuda ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Soft Tissue ◽  
Prognostic Value ◽  
Doubling Time ◽  
Soft Tissue Tumors ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Primary Bone

The prognostic value of CINSARC in a randomised trial comparing histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e23531-e23531 ◽  
Author(s):  
Sandro Pasquali ◽  
Luca Braglia ◽  
Frederic Chibon ◽  
Jean Michel Coindre ◽  
Antoine Italiano ◽  
...  
Keyword(s):  
Gene Expression ◽  
High Risk ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Preoperative Chemotherapy ◽  
Prognostic Value ◽  
Randomised Trial ◽  
Tumour Response ◽  
Soft Tissue Sarcomas ◽  
Standard Chemotherapy

e23531 Background: The Complexity INdex in SARComas (CINSARC) is a gene expression signature related to mitosis and chromosome integrity that stratifies risk for recurrence of soft tissue sarcoma (STS) patients. The aim of this study was to validate the prognostic value of CINSARC in patients enrolled in a randomised trial that compared histotype-tailored neoadjuvant chemotherapy with standard chemotherapy in patients with high-risk STS (ISG-STS 1001). Methods: CINSARC is 67-gene-expression-based signature that has been previously tested in retrospective series. The ISG-STS 1001 was a phase 3 RCT comparing histotype-tailored and anthracycline-based chemotherapy in localised, high-risk STS of the extremities or trunk wall, with one of five histological STS subtypes: high-grade myxoid liposarcoma, leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumour, and undifferentiated pleomorphic sarcoma. Outcome variables were disease-free survival (DFS), overall survival (OS) and tumour response according to RECIST v1.1. Results: CINSARC was assessed in pre-treatment biopsies of 87 in 435 patients participating in the study. Thirty and 57 patients segregated in the lower (C1) and higher (C2) CINSARC risk group, respectively. Incidence of local recurrences (LR) and distant metastasis (DM) did not differ between C1 and C2 CINSARC groups [2 (6.6%) and 11 (19.3%) patients had a LR, respectively, and 10 (33.3%) and 14 (24.5%) patients had DM, respectively, P = 0.800]. Consistently, we did not observe statistically significant differences for DFS and OS between patients in the CINSARC C1 and C2 groups (log-rank test, P = 0.522 and P = 0.480, respectively). RECIST tumour response was analysed in a subset of patients (N = 39), showing that a RECIST SD was more likely in C1 (N = 12/14, 85.6%) compared to C2 (N = 18/25, 72%) group, while both RECIST PD and PR were more commonly detected in C2 [3/25 (12%) and 4/25 (16%), respectively] compared to C1 [0/14 (0%) and 1/14 (7.1%), respectively] group. Conclusions: In high-risk STS patients treated with preoperative chemotherapy within a RCT, CINSARC did not correlate with different DFS and OS. While this may well be due to a failure of this gene signature in this patient population, an alternative hypothesis is that preoperative chemotherapy may improve the prognosis of higher-risk patients. Clinical trial information: NCT01710176 .

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Benign Skin and Soft-Tissue Tumors of the Hand

1987 ◽  
Vol 14 (2) ◽  
pp. 403-412
Author(s):  
Saleh M. Shenaq
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Tumors ◽  
Tumors Of The Hand

Percutaneous Imaging-Guided versus Open Musculoskeletal Biopsy: Concepts and Controversies

2020 ◽  
Vol 24 (06) ◽  
pp. 667-675
Author(s):  
Violeta Vasilevska Nikodinovska ◽  
Slavcho Ivanoski ◽  
Milan Samardziski ◽  
Vesna Janevska
Keyword(s):  
Soft Tissue ◽  
Complication Rate ◽  
Core Needle Biopsy ◽  
Multidisciplinary Team ◽  
Gold Standard ◽  
Needle Biopsy ◽  
Soft Tissue Tumors ◽  
Open Biopsy ◽  
Core Needle ◽  
Similar Accuracy

AbstractBone and soft tissue tumors are a largely heterogeneous group of tumors. Biopsy of musculoskeletal (MSK) tumors is sometimes a challenging procedure. Although the open biopsy is still considered the gold standard for the biopsy of MSK lesions, core needle biopsy can replace it in most cases, with similar accuracy and a low complication rate. The biopsy should be performed in a tertiary sarcoma center where the multidisciplinary team consists of at minimum a tumor surgeon, an MSK pathologist, and an MSK radiologist who can assess all steps of the procedure. Several factors can influence the success of the biopsy including the lesion characteristics, the equipment, and the method used for the procedure. This review highlights some of the important aspects regarding the biopsy of the MSK tumors, with special attention to imaging a guided core needle biopsy and highlighting some of the recent advancements and controversies in the field.

Evaluation of Lipomatous Soft Tissue Tumors by MR Imaging

1994 ◽  
Vol 35 (4) ◽  
pp. 367-370 ◽  
Author(s):  
J. Gelineck ◽  
J. Keller ◽  
O. Myhre Jensen ◽  
O. Steen Nielsen ◽  
T. Christensen
Keyword(s):  
Soft Tissue ◽  
Mr Imaging ◽  
Soft Tissue Tumors

Diagnostic Imaging of Fetal and Neonatal Abdominal and Soft Tissue Tumors

2015 ◽  
Vol 11 (3) ◽  
pp. 143-150 ◽  
Author(s):  
Usha D. Nagaraj ◽  
Beth M. Kline-Fath
Keyword(s):  
Soft Tissue ◽  
Diagnostic Imaging ◽  
Soft Tissue Tumors

Imaging of soft tissue tumors

2020 ◽  
Vol 16 ◽  
Author(s):  
Shinji Tsukamoto ◽  
Andreas F. Mavrogenis ◽  
Yasuhito Tanaka ◽  
Costantino Errani
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Soft Tissue ◽  
Tumor Size ◽  
Critical Role ◽  
Evaluation Criteria ◽  
Soft Tissue Tumors ◽  
Resonance Imaging ◽  
Benign Soft Tissue Tumors ◽  
Response To Chemotherapy

: Differentiation of malignant from benign soft tissue tumors is challenging with imaging alone, including that by magnetic resonance imaging and computed tomography. However, the accuracy of this differentiation has increased owing to the development of novel imaging technology. Detailed patient history and physical examination remain essential for differentiation between benign and malignant soft tissue tumors. Moreover, measurement only of tumor size based on Response Evaluation Criteria In Solid Tumors criteria is insufficient for the evaluation of response to chemotherapy or radiotherapy. Change in metabolic activity measured by 18F-fluorodeoxyglucose positron emission tomography or dynamic contrast enhanced-derived quantitative endpoints can more accurately evaluate treatment response compared to change in tumor size. Magnetic resonance imaging can accurately evaluate essential factors in surgical planning such as vascular or bone invasion and “tail sign”. Thus, imaging plays a critical role in the diagnosis and treatment of soft tissue tumors.

Sign in / Sign up

Export Citation Format

Share Document